Covidien sees strength in medical device unit as profits rise

The medical devices earnings news kept rolling in last week with Covidien ($COV) reporting good news with its medical device unit, which saw sales of $1.98 billion in the fiscal 2012 first quarter that ended in December, up 6% from $1.88 billion a year earlier. The company's results beat analyst expectations and sent its stock up, the Boston Business Journal reported. Covidien also saw profits of $494 million during the quarter, up from $427 million last year. Covidien release | More

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.